Senate
File
552
-
Introduced
SENATE
FILE
552
BY
COMMITTEE
ON
HEALTH
AND
HUMAN
SERVICES
(SUCCESSOR
TO
SSB
1138)
A
BILL
FOR
An
Act
relating
to
a
review
of
anti-obesity
medications
by
the
1
department
of
health
and
human
services
and
the
department
2
of
administrative
services
for
purposes
of
the
medical
3
assistance
program
and
health
insurance
plans
for
state
4
employees.
5
BE
IT
ENACTED
BY
THE
GENERAL
ASSEMBLY
OF
THE
STATE
OF
IOWA:
6
TLSB
1939SV
(2)
91
lh/ko
S.F.
552
Section
1.
ANTI-OBESITY
MEDICATION
REVIEW
AND
REPORT.
For
1
purposes
of
the
medical
assistance
program
under
chapter
249A
2
and
health
insurance
plans
for
state
employees
established
3
pursuant
to
chapter
509A,
the
department
of
health
and
human
4
services
and
the
department
of
administrative
services
shall
5
review
anti-obesity
medications,
including
GLP-1
agonists,
6
for
effectiveness
relating
to
weight
loss,
the
impact
7
on
comorbidities,
the
potential
for
cost
savings
due
to
8
deferred
medical
procedures
and
reduced
medications
related
9
to
comorbidity,
recommended
eligibility
requirements,
any
10
short-term
and
long-term
costs
associated
with
coverage,
11
and
any
other
criteria
the
departments
deem
relevant.
The
12
department
of
health
and
human
services
and
the
department
of
13
administrative
services
shall
submit
a
report
to
the
general
14
assembly
by
January
5,
2026,
with
the
departments’
findings,
15
proposed
eligibility
requirements,
and
any
short-term
and
16
long-term
costs
associated
with
coverage.
17
EXPLANATION
18
The
inclusion
of
this
explanation
does
not
constitute
agreement
with
19
the
explanation’s
substance
by
the
members
of
the
general
assembly.
20
This
bill
relates
to
the
department
of
health
and
human
21
services
(HHS)
and
the
department
of
administrative
services
22
(DAS)
review
of
anti-obesity
medication
for
purposes
of
the
23
medical
assistance
program
and
health
insurance
plans
for
state
24
employees
established
pursuant
to
Code
chapter
509A.
25
The
bill
requires
HHS
and
DAS
to
review
anti-obesity
26
medications,
including
GLP-1
agonists,
for
effectiveness,
27
comorbidities,
cost
savings,
eligibility
requirements,
and
28
short-term
and
long-term
costs
associated
with
coverage.
HHS
29
and
DAS
shall
submit
a
report
to
the
general
assembly
by
30
January
5,
2026,
containing
HHS’s
and
DAS’s
findings,
proposed
31
eligibility
requirements,
and
any
short-term
and
long-term
32
costs
associated
with
coverage.
33
-1-
LSB
1939SV
(2)
91
lh/ko
1/
1